ReviewJHEP reports : innovation in hepatology2020
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
Review in JHEP reports : innovation in hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Prevalence of systemic complications of COVID-19 in critically ill patients: systematic review with meta-analysis.Revista latino-americana de enfermagem · 2025Pooled it
- Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.International journal of clinical practice · 2022Pooled it
- The risk of hepatitis B virus reactivation in COVID-19 patients treated with corticosteroids: a retrospective observational cohort study.BMC infectious diseases · 2026Observational
- Post-COVID-19 Pandemic Sequelae in Liver Diseases.Life (Basel, Switzerland) · 2025Review
- Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.Frontiers in immunology · 2025Review
- COVID-19 Challenges in Autoimmune Hepatitis Management: A Successful Outcome With Intravenous Immune Globulin (IVIg).Case reports in gastrointestinal medicine · 2025Article
- Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.Inflammopharmacology · 2024Review
- Trends in Hospitalizations of Patients with Hepatitis C Virus in Poland between 2012 and 2022.Journal of clinical medicine · 2024Article
- The Silent Syndrome of Long COVID and Gaps in Scientific Knowledge: A Narrative Review.Viruses · 2024Review
- Wilson Disease and the COVID-19 pandemic: exploring patients' mental health and vaccination attitudes in a longitudinal study.Frontiers in psychology · 2024Article
- Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?Endocrine, metabolic & immune disorders drug targets · 2024Article
- Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis.Journal of clinical medicine · 2023Article
- The Impact of Viral and Bacterial Co-Infections and Home Antibiotic Treatment in SARS-CoV-2 Hospitalized Patients at the Policlinico Tor Vergata Hospital, Rome, Italy.Antibiotics (Basel, Switzerland) · 2023Article
- Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.Cancers · 2023Article
- Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.Journal of gastrointestinal cancer · 2023Review
- Autoimmune liver diseases and SARS-CoV-2.World journal of gastroenterology · 2023Review
- Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients.World journal of gastroenterology · 2023Review
- Liver and Biliary Tract Disease in Patients with Coronavirus disease-2019 Infection.Gastroenterology clinics of North America · 2023Review
- Implications of metabolic dysfunction associated fatty liver disease in COVID-19.World journal of clinical cases · 2023Review
- COVID-19 and liver injury in individuals with obesity.World journal of gastroenterology · 2023Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare systems are returning to a more normal routine, many countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is significantly impacting on the care of these patients. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the disease course must be kept in mind when caring for patients with COVID-19. This review should serve as an update on the previous position paper, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.